Overweight and obesity killer Lorcaserin and Oristat

free bootstrap template

Lorcaserin (Belviq)

Lorcaserin is used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and keep from gaining back that weight. Lorcaserin must be used along with a reduced calorie diet and an exercise plan.
The drug works by controlling appetite — specifically by activating brain receptors for serotonin, a neurotransmitter that triggers feelings of satiety and satisfaction.Acts on the serotonin receptors in your brain. May help you feel full after eating smaller amounts of food.
Side effects of lorcaserin could be constipation,cough,dizziness,dry mouth,feeling tired,headaches and nausea.Lorcaserin, used in combination with diet and exercise, results in modest weight loss of about 12.9 lb (5.8 kg) compared with 5.6 lb (2.5 kg) with placebo

Orlistat (Xenical)

Orlistat (Xenical) is available in lower dose without prescription (Alli),Adults and children ages 12 and older can take Orlistat.
Orlistat works in your gut to reduce the amount of fat your body absorbs from the food you eat,Orlistat Side effects could be diarrhea,gas,leakage of oily stools and stomach pain
Rare cases of severe liver injury have been reported. Avoid taking with cyclosporine. Take a multivitamin pill daily to make sure you get enough of certain vitamins that your body may not absorb from the food you eat.


1. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, et al. (May 2008). "Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization". The Journal of Pharmacology and Experimental Therapeutics. 325 (2): 577–87. doi:10.1124/jpet.107.133348. PMID 18252809.
2. US patent 6953787, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2003-10-04, issued 2005-11-10
3. US patent 7704993, Brian Smith, Charles A. Gilson, III, Jeffrey Schultz, Jeffrey Smith, "Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases", published 2004-16-06, issued 2010-27-04
4. US patent 8207158, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2011-27-05, issued 2012-26-06

Check here: lorcaserin hcl powder